Healthcare Industry News:  Multiple Myeloma  

Biopharmaceuticals Personnel

 News Release - October 15, 2007

Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs

ANN ARBOR, Mich., Oct. 15 (HSMN NewsFeed) -- Velcura Therapeutics, Inc. has named Jeffrey N. Fellows, a biotechnology regulatory executive with more than 20 years of successful regulatory experience, as Vice President of Regulatory Affairs.

Velcura Therapeutics President and CEO Michael W. Long, PhD, said, "Jeff is a great addition to our senior management team. He will be responsible for our clinical trials applications, regulatory compliance and interactions with the Federal Drug Administration. His more than two decades of experience will be critical in helping Velcura navigate the regulatory path for VEL-0230, our new drug that stimulates bone formation and inhibits bone loss." Dr. Long added, "Jeff's past experience with the Oncology Division at FDA is a definite plus as our initial clinical trial of VEL-0230 in patients will be for treatment for Multiple Myeloma Bone Disease, a blood cancer associated with profound bone loss."

Immediately before joining Velcura Therapeutics, Fellows was Vice President of Regulatory Affairs for Cell Therapeutics, Inc. in Seattle, where for the past three years he was the main liaison with the FDA and responsible for the development of global regulatory strategy and agency filings for the oncology focused company.

Prior to CTI, Fellows worked for Amgen Inc. in Thousand Oaks, CA, and worked in a series of increasingly responsible positions, eventually serving as Director of Regulatory Affairs and Global Regulatory Team Leader in Thousand Oaks, California. There Fellows served on Corporate Global Product Strategy Teams for early- and late-stage development compounds and led Global Regulatory Teams in the United States, Europe, Canada, Australia, and Japan.

After graduation from Oregon State University with a Bachelor of Science in Microbiology, Fellows began his career in regulatory affairs at NeoRx Corporation, where he prepared Investigational New Drug Applications for anti- cancer products. He worked for Synergen, Inc. in Boulder, Colorado, from 1990 until Amgen purchased Synergen in late 1994.

Jeffery Fellows lives in Woodway, Washington, and will work from Velcura's Seattle office.

About Velcura Therapeutics®, Inc.

Velcura Therapeutics, Inc. is an early-stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to better understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both anabolic bone-building and anti- bone-loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize compounds that both simulate and inhibit bone growth. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at www.velcura.com


Source: Velcura Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.